Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Rogers, Kathryn ^a,h   Felsenstein, Kevin M ^a,i   Hrdlicka, Lori ^a   Tu, Zhiming ^a   Albayya, Faris ^a   Lee, Winnie ^a,j   Hopp, Sarah ^a,k   Miller, Mary Jo ^a,l   Spaulding, Darcie ^a   Yang, Zhiyong ^a,m   Hodgdon, Hilliary ^a   Nolan, Scott ^a   Wen, Melody ^a   Costa, Don ^a   Blain, Jean Francois ^a   Freeman, Emily ^a   De Strooper, Bart ^b,c   Vulsteke, Veerle ^b,c   Scrocchi, Louise ^d,n   Zetterberg, Henrik ^e,f   Portelius, Erik ^e   Hutter Paier, Birgit ^g   Havas, Daniel ^g   Ahlijanian, Michael ^a,o   Flood, Dorothy ^a   Leventhal, Liza ^a   Shapiro, Gideon ^a,p   Patzke, Holger ^a   Chesworth, Richard ^a,q   Koenig, Gerhard ^a   more..

^a EnVivo Pharmaceuticals Inc   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Amorfix Life Sciences   (Canada)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g QPS Austria GmbH   (Austria)

^h CoMentis Research Facility ^*  (United States)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^j EISAI INC   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l Galenea Corporation   (United States)

^m UNIVERSITY OF MARYLAND   (United States)

ⁿ Apotex Inc   (Canada)

^o BRISTOL MYERS SQUIBB   (United States)

^p Pharmore Inc   (United States)

^q EPIZYME INC   (United States)

more..

Author keywords

secretase; Alzheimer's disease; Amyloid; Cognition; Modulation; NSAID

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE; EPHRIN A4; EVP 0015962; GAMMA SECRETASE; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; COGNITIVE DEFECT; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NEUROMODULATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALIA; MUS;

EID: 84871151505     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-61     Document Type: Article

References (63)

1. Über eine eigenartige erkrankung der hirnrinde. Alzheimer A, Allg Zschr Psychiatr 1907 64 146 148
2. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnositc guidelines for Alzheimer's disease. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH, Alzheimers Dement 2011 7 263 269 10.1016/j.jalz.2011.03.005 21514250
3. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
4. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
5. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y, Neuron 1994 13 45 53 10.1016/0896-6273(94)90458-8 8043280
6. Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S, Neurosci Lett 1996 215 173 176 10.1016/0304-3940(96)12970-0 8899741 (Pubitemid 26323454)
7. Alzheimer's disease and the β-amyloid peptide. Murphy MP, LeVine H III, J Alzheimers Dis 2010 19 311 323 20061647
8. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
9. Presenilin: running with scissors in the membrane. Selkoe DJ, Wolfe MS, Cell 2007 131 215 221 10.1016/j.cell.2007.10.012 17956719 (Pubitemid 47576152)
10. Amyloid precursor protein trafficking, processing, and function. Thinakaran G, Koo EH, J Biol Chem 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
11. Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. Beher D, Wrigley JD, Owens AP, Shearman MS, J Neurochem 2002 82 563 575 10.1046/j.1471-4159.2002.00985.x 12153480 (Pubitemid 34835674)
12. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Karran E, Mercken M, De Strooper B, Nat Rev Drug Discov 2011 10 698 712 10.1038/nrd3505 21852788
13. γ-secretase substrates and their implications for drug development in Alzheimer's disease. Lleó A, Saura CA, Curr Top Med Chem 2011 11 1513 1527 10.2174/156802611795861004 21510835
14. The physiology of the β-amyloid precursor protein intracellular domain AICD. Pardossi-Piquard R, Checler F, J Neurochem 2012 120 Suppl 1 109 124 22122663
15. A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R, Nature 1999 398 518 522 10.1038/19083 10206645 (Pubitemid 29177491)
16. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee H-JJ, Zhang L, Higgins GA, Parker EM, J Biol Chem 2004 279 12876 12882 14709552 (Pubitemid 38445862)
17. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ, Arch Neurol 2008 65 1031 1038 10.1001/archneur.65.8.1031 18695053
18. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A, Expert Opin Investig Drugs 2011 20 325 341 10.1517/13543784.2011.550572 21222550
19. Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N, J Neurosci 2012 32 2037 2050 10.1523/JNEUROSCI.4264-11.2012 22323718
20. Inflammation and Alzheimer's disease. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M, Landreth G, Lue L-F, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, et al. Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586 (Pubitemid 30349107)
21. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Ferretti MT, Cuello AC, Curr Alzheimer Res 2011 8 164 174 10.2174/156720511795255982 21345170
22. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH, Nature 2001 414 212 216 10.1038/35102591 11700559 (Pubitemid 33051236)
23. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH, J Biol Chem 2003 278 31831 31837 10.1074/jbc.M303592200 12805356 (Pubitemid 37048365)
24. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NFκB, do not reduce amyloid β42 production. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH, J Biol Chem 2003 278 31825 31830 10.1074/jbc.M303588200 12805355 (Pubitemid 37048364)
25. 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]4-yl) -cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A, J Pharmacol Exp Ther 2007 323 822 830 10.1124/jpet.107.129007 17895400 (Pubitemid 350146064)
26. Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li Y-M, Sisodia SS, Tanzi RE, Wagner SL, Neuron 2010 67 769 780 10.1016/j.neuron.2010.08.018 20826309
27. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Van Broeck B, Chen JM, Tréton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, Rowley A, Br J Pharmacol 2011 163 375 389 10.1111/j.1476-5381.2011. 01207.x 21232036
28. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h. Hawkins J, Harrsion DC, Ahmed S, Davis RP, Chapman T, Marshall I, Smith B, Mead TL, Medhurst A, Giblin GMP, Hall A, Gonzalez MI, Richardson J, Hussain I, Neurodegener Dis 2011 8 455 464 10.1159/000324511 21389687
29. First and second generation gamma-secretase modulators (GSMs) modulate abeta production through different mechanisms. Borgegard T, Juréus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, Waldman M, Stromberg K, Nord J, Johansson J, Regner A, Parpal S, Malinowsky D, Radesater A-C, Li T, Singh R, Eriksson H, Lundkvist J, J Biol Chem 2012 287 11810 11819 10.1074/jbc.M111.305227 22334705
30. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, Barbour R, Bova M, Chen X-H, Dappen MS, Eichenbaum T, Goldbach E, Hawkinson J, Lawler-Herbold R, Hu K, Hui T, Jagodzinski JJ, Keim PS, Kholodenko D, Latimer LH, Lee M, Marugg J, Mattson MN, McCauley S, Miller JL, Motter R, Mutter L, Neitzel ML, Ni H, Nguyen L, et al. Alzheimers Res Ther 2010 2 36 10.1186/alzrt60 21190552
31. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. Saxena MT, Schroeter EH, Mumm JS, Kopan R, J Biol Chem 2001 276 40268 40273 11518718
32. Cellular mechanisms of β-amyloid production and secretion. Sinha S, Lieberburg I, Proc Natl Acad Sci USA 1999 96 11049 11053 10.1073/pnas.96.20. 11049 10500121 (Pubitemid 29487325)
33. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. DeStrooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F, Nature 1998 391 387 340 10.1038/34910 9450754 (Pubitemid 28093512)
34. Effects of PS1 deficiency on membrane protein trafficking in neurons. Naruse S, Thinakaran G, Luo JJ, Kusiak JW, Tomita T, Iwatsubo T, Qian X, Ginty DD, Price DL, Borchelt DR, Wong PC, Sisodia SS, Neuron 1998 5 1213 1221 (Pubitemid 29018089)
35. Synaptic activity prompts γ-secretase-mediated cleavage of EphA4 and dendritic spine formation. Inoue E, Deguchi-Tawarada M, Togawa A, Matsui C, Arita K, Katahira-Tayama S, Sato T, Yamauchi E, Oda Y, Takai Y, J Cell Biol 2009 185 551 564 10.1083/jcb.200809151 19414612
36. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G, Science 1996 274 99 102 10.1126/science.274.5284.99 8810256 (Pubitemid 26332733)
37. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG, J Neurosci 2001 21 372 381 11160418 (Pubitemid 32107428)
38. Hippocampus and contextual fear conditioning: recent controversies and advances. Anagnostaras SG, Gale GD, Fanselow MS, Hippocampus 2001 11 8 17 10.1002/1098-1063(2001)11:1<8::AID-HIPO1015>3.0.CO;2-7 11261775
39. Acute γ-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL, J Neurosci 2005 25 8898 8902 10.1523/JNEUROSCI.2693-05.2005 16192379 (Pubitemid 41384457)
40. CHF5074, A novel γ-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. Imbimbo BP, Giardino L, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, D'Arrigo A, Leon A, Villetti G, Calzà L, J Alzheimers Dis 2010 20 159 173 20164581
41. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. McGeer PL, McGeer EG, Neurobiol Aging 2007 28 639 647 10.1016/j.neurobiolaging.2006.03.013 16697488 (Pubitemid 46349357)
42. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM, J Neurosci 2000 20 5709 5714 10908610 (Pubitemid 30636898)
43. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G, J Neurosci 2003 23 7504 7509 12930788 (Pubitemid 37034066)
44. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE, J Clin Invest 2003 112 440 449 12897211 (Pubitemid 38063773)
45. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase II Study Investigators, Lancet Neurol 2008 7 483 493 10.1016/S1474-4422(08)70090-5 18450517
46. Selected non-steroidal anti-inflammatroy drugs and their derivatives target γ-secretase at a novel site: evidence for an allosteric mechanism. Beher D, Clarke EE, Wrigley JDJ, Martin ACL, Nadin A, Churcher I, Shearman MS, J Biol Chem 2004 279 43419 43426 10.1074/jbc.M404937200 15304503 (Pubitemid 39390641)
47. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease: a randomized controlled trial. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase III Study Group, JAMA 2009 302 2557 2564 10.1001/jama.2009. 1866 20009055
48. γ-secretase modulators as potential disease modifying anti-Alzheimer's drugs. Oehlrich D, Bertholet DJ-C, Gijsen HJM, J Med Chem 2011 54 669 698 10.1021/jm101168r 21141968
49. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH, J Neurosci 2002 22 1858 1867 11880515 (Pubitemid 35386304)
50. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. Kuo Y-M, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE, J Biol Chem 2001 276 12991 12998 10.1074/jbc.M007859200 11152675
51. A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K, Neurobiol Dis 2008 31 46 57 10.1016/j.nbd.2008.03.005 18504134
52. Detection and quantitation of amyloid B-peptide with 2 monoclonal antibodies. Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza VJ, Hong H, Wisniewski HM, Neurosci Res Commun 1990 7 113 122
53. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D, Exp Neurol 2002 173 183 195 10.1006/exnr.2001.7754 11822882 (Pubitemid 34151370)
54. Shapiro G, Chesworth R, Tetrasubstituted benzenes PCT publication WO2009/086277 2009
55. APP substitutions V715F and L720P alter PS1 conformation and differentially affect Aβ and AICD generation. Tesco G, Ginestroni A, Hiltunen M, Kim M, Dolios G, Hyman BT, Wang R, Berezovska O, Tanzi RE, J Neurochem 2005 95 446 456 10.1111/j.1471-4159.2005.03381.x 16086682 (Pubitemid 41457513)
56. Optimized survival of hippocampal neurons in B27-supplemented neurobasal™, a new serum-free medium combination. Brewer GJ, Torricelli JR, Evege EK, Price PJ, J Neurosci Res 1993 35 567 576 10.1002/jnr.490350513 8377226 (Pubitemid 23215708)
57. Defined media for dissociated neural cultures. Bottenstein JE, Current Methods in Cellular Neurobiology John Wiley and Sons, New York, Barker JL, McKelvy JF, 1983 107 130 Volume 4
58. Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence. Miller DL, Potempska A, Mehta PD, Amyloid 2007 14 39 50 10.1080/13506120601116500 17453624 (Pubitemid 46491164)
59. Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. Portelius E, Tran AJ, Andreasson U, Pesson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A, J Proteome Res 2007 6 4433 4439 10.1021/pr0703627 17927230 (Pubitemid 350158518)
60. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Serneels L, Dejaegere T, Craessaerts K, Horré K, Jorissen E, Tousseyn T, Hébert S, Coolen M, Martens G, Zwijsen A, Annaert W, Hartmann D, De Strooper B, Proc Natl Acad Sci USA 2005 102 1719 1724 10.1073/pnas.0408901102 15665098 (Pubitemid 40209234)
61. Altered cleavage and secretion of a recombinant β-APP bearing the Swedish familial Alzheimer's disease mutation. Felsenstein KM, Hunihan LW, Roberts SB, Nat Genet 1994 6 251 256 10.1038/ng0394-251 8012386 (Pubitemid 24188621)
62. Presenilin clinical mutations can affect γ-secretase activity by different mechanisms. Bentahir M, Nyabi O, Verhamme J, Tolia A, Katrien Horré K, Wiltfang J, Esselmann H, De Strooper B, J Neurochem 2006 96 732 742 10.1111/j.1471-4159.2005.03578.x 16405513
63. Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. Tanghe A, Termont A, Merchiers P, Schilling S, Demuth H-U, Scrocchi L, Van Leuven F, Griffioen G, Van Dooren T, Int J Alzheimers Dis 2010 ii 417314 10.4061/2010/417314